Lidocaine levels measured in brain tumors during surgery

NCT ID NCT04716699

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 trial measured how much lidocaine, a common pain reliever, reaches the tumor and blood in 12 adults undergoing surgery for glioblastoma. Researchers collected blood and tumor samples at multiple times to understand the drug's levels. The goal was to gather information that might help develop future treatments for this aggressive brain cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

lidocaine

What this could lead to

If successful, this study could help researchers design new treatments that use lidocaine to improve outcomes for glioblastoma patients.

What could go wrong

This is a very small, early-phase study with only 12 participants, focused on measuring drug levels rather than proving any treatment benefit. It may not lead to any new therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States